http://kanab.utah.gov/aberad.php?pharmac... http://kanab.utah.gov/aberad.php?pharmac... viagra 100 mg prezzo levitra mg vieille pharmacie acheter du cialis moins cher médicament viagra rennes legislation vente libre viagra suisse acheter du levitra en ligne viagra homme et femme be farmacia online cialis vente viagra canada acquisto tadalafil online http://www.mp3doctor.com/aleo.php?es=313... disulfiram pharmacie http://www.mp3doctor.com/aleo.php?es=312...
acheter du cialis viagra au meilleur prix achat cialis suisse
  • levitra pris acheter viagra veritable acheter cialis 5 milligrams
  • HPV-Positive Oropharyngeal Patients Show Overall Higher Survival Rate Compared to HPV-Negative Patients

    Tue, Feb 25, 2014

    Oral Cancer News

    Source: eurekalert.org
    Published: February 20, 2014
    By: Michelle Kirkwood
     

    Scottsdale, Ariz., February 20, 2014—A retrospective analysis of oropharyngeal patients with recurrence of disease after primary therapy in the Radiation Therapy Oncology Group (RTOG) studies 0129 or 0522 found that HPV-positive patients had a higher overall survival (OS) rate than HPV-negative patients (at two years post-treatment, 54.6 percent vs. 27.6 percent, respectively), according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

    The analysis included 181 patients with stage III-IV oropharyngeal squamous cell carcinoma (OPSCC) with known HPV status (HPV-positive = 105; HPV-negative = 76), and cancer progression that was local, regional and/or distant after completion of primary cisplatin-based chemotherapy and radiation therapy (standard vs. accelerated fractionation (AFX)) in RTOG 0129 or cisplatin-AFX with or without cetuximab in RTOG 0522. Tumor status was determined by a surrogate, p16 immunohistochemistry.

    Median time to progression was virtually the same for HPV-positive and HPV-negative patients (8.2 months vs. 7.3 months, respectively). Increased risk of death in univariate analysis was associated with high tumor stage at diagnosis (T4 vs. T2-T3), fewer on-protocol cisplatin cycles (≤1 vs. 2-3) and distant vs. local/regional recurrent (for all, hazard ratios (HRs) >2.0 and p<0.05). Risk of death after disease progression increased by 1 percent per cigarette pack-year at diagnosis. Rates were estimated by Kaplan-Meier method and compared by log-rank. HRs were estimated by Cox proportional hazards models and stratified by treatment protocol.

    In addition, HPV-positive and HPV-negative patients who underwent surgery after cancer recurrence also experienced improved OS compared to those who did not undergo surgery. (The effect may have been more pronounced among HPV-positive than HPV-negative patients.) Recurrence is most commonly in the lungs for both groups of patients.

    “Our findings demonstrate that HPV-positive OPSCC patients have significantly improved survival after progression of disease when compared with HPV-negative patients. Median survival after disease progression was strikingly longer for HPV-positive than HPV-negative patients,” said lead author Carole Fakhry, MD, MPH, assistant professor in the Department of Otolaryngology Head and Neck Surgery at Johns Hopkins Medicine in Baltimore. “These findings provide us with valuable knowledge to better counsel and treat patients.”

     

    * This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

     

    Print Friendly
    Be Sociable, Share!
    , , , ,

    Leave a Reply

    You must be logged in to post a comment.